About NATRS

Purpose

The National Adenovirus Type Reporting System (NATRS) is a passive laboratory-based surveillance system that coordinates reporting of laboratory detections of human adenovirus types in the United States.

Adenovirus

Overview

CDC encourages participating laboratories to report typed human adenovirus detections accompanied by limited demographic, clinical, and laboratory data.

Type-based human adenovirus surveillance in the United States has three objectives:

  • Determine circulation patterns of human adenovirus types.
  • Assist with recognition and confirmation of outbreaks associated with circulating types.
  • Inform development or use of diagnostic tests, therapeutics, and vaccines.

Participating sites

Since 2014–2019, 15 laboratories from across the United States reported data to NATRS:

  • The CDC Respiratory Virology Laboratory
  • Public health laboratories from nine states
  • Two clinical laboratories
  • Two university laboratories
  • One Department of Defense laboratory

What data we collect

Data are collected from collaborating public health and clinical laboratories in the United States. Laboratories report human adenovirus detections on a quarterly basis to CDC by:

  • species and human adenovirus type
  • specimen type
  • collection date
  • age
  • sex

NATRS collects data from participating laboratories using a simplified report form. This allows for determination of trends in type-specific human adenovirus circulation and more timely recognition and documentation of outbreaks.

Laboratories with the capacity to type are encouraged to report to NATRS to help improve geographic and temporal surveillance.

Surveillance data

Most Common Human Adenovirus Species and Types Reported in the U.S., 2014-2017

Species and Type and (Percent of Detections)

  • A12 (0.3); A31 (0.3
  • B3 (22.3); B7 (12.9); B11 (0.2); B14 (4.1)
  • B21 (1.6); B34 (0.2); B35 (0.5)
  • C1 (14.7); C2 (19.6); C5 (3.4); C6 (1.2)
  • D8 (3.4); D15 (0.1); D19 (0.2); D22 (0.1)
  • D29 (0.1); D37 (0.7); D53 (0.6); D56 (0.1)
  • E4 (13.4)
  • F41 (0.2)

Detections were reported in specimens from 32 states and the U.S. Virgin Islands.

For more information about the most recent human adenovirus data, see CDC MMWR Human Adenovirus Surveillance – United States, 2003-2016.

Publications

NATRS data are made available to public health professionals, health care providers, and the public.